Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity

Fineline Cube Dec 19, 2025
Company Drug

Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo

Fineline Cube Dec 19, 2025
Company Drug

Genor Biopharma Gains NMPA Approval for CDK4/6 Inhibitor Lerociclib in China

Fineline Cube May 30, 2025

China’s Genor Biopharma Co., Ltd (HKG: 6998) announced that it has received marketing clearance from...

Company Deals

Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development

Fineline Cube May 30, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...

Company Deals

Danaher Partners with AstraZeneca to Advance Precision Medicine

Fineline Cube May 30, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with...

Company Drug

Innovent Biologics Doses First Patient in Phase III Psoriasis Trial for Picankibart

Fineline Cube May 30, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first subject dosing in a Phase III...

Company Drug

GSK Halts PIVOT-PO Trial Early as Tebipenem HBr Meets Efficacy Targets for cUTI

Fineline Cube May 30, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the early termination of the pivotal Phase...

Company Drug

Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency

Fineline Cube May 30, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...

Company Drug

Regend Therapeutics Gains NMPA Approval for Phase I/II Study of REGEND003 in Diabetes-Related CKD

Fineline Cube May 30, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that it has received approval from China’s...

Company Deals

Ganzhou Hemay Pharma Files for HK IPO with SDIC Securities Sponsorship

Fineline Cube May 30, 2025

China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with...

Company Deals

GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation

Fineline Cube May 29, 2025

Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD...

Company Medical Device

Abbott Laboratories Receives FDA Approval for Tendyne TMVR System

Fineline Cube May 29, 2025

US-based medical device giant Abbott Laboratories (NYSE: ABT) announced that it has received marketing approval...

Company Deals

AusperBio Secures $50M in Oversubscribed Series B+ Round to Advance Hepatitis B Therapy

Fineline Cube May 29, 2025

Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing...

Company Drug

BMS Gains European Approval for Opdivo Subcutaneous Formulation

Fineline Cube May 29, 2025

Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to...

Company Drug

Novartis’ Fabhalta Approved for Previously Treated PNH Patients in China

Fineline Cube May 29, 2025

The China unit of Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that the National Medical...

Company Drug

InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248

Fineline Cube May 29, 2025

Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical...

Company Deals

Fosun Pharma and Jiuyuan Gene Partner to Commercialize Biologics in Global Markets

Fineline Cube May 29, 2025

Chinese pharmaceutical firms Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196; HKG: 2196) and Hangzhou...

Company Drug

Lupeng Pharma’s Rocbrutinib Near Approval for Mantle Cell Lymphoma

Fineline Cube May 29, 2025

Guangzhou Lupeng Pharmaceutical Co., Ltd’s rocbrutinib is currently under New Drug Application (NDA) review at...

Company Deals

Viva Biotech Establishes RMB 300M Fund for Early-Stage Pharma Projects

Fineline Cube May 29, 2025

China-based Contract Research Organization (CRO) Viva Biotech (HKG: 1873) announced that its wholly-owned subsidiary, Hangzhou...

Company Drug

Bayer’s Sevabertinib Receives FDA Priority Review for HER2-mutant NSCLC

Fineline Cube May 29, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its investigational oral small-molecule tyrosine kinase...

Company Drug

JW Therapeutics’ Carteyva Receives Fourth sBLA for r/r LBCL

Fineline Cube May 29, 2025

JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...

Company Medical Device

Sino Medical Sciences Technology’s AUCURA Flow-Diverting Stent Approved by NMPA

Fineline Cube May 29, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its holding subsidiary Neurovita has...

Posts pagination

1 … 86 87 88 … 599

Recent updates

  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
  • Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo
  • Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network
  • Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee
  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity

Company Drug

Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo

Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Others

Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.